The drug formulation market is projected to expand from USD 1.7 trillion in 2025 to USD 2.8 trillion by 2035, growing at a ...

Creative Biolabs recently rolled out a three-dimensional upgrade designed to make antibodies safer, more potent, and easier to develop. SHIRLEY, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- ...

For children with severe Crohn disease, upadacitinib offers an effective induction therapy, but its benefits must be carefully weighed against potential adverse events.

A biosimilar is a medicine that is very similar ... it to the most suitable pharmacy based on the member’s benefit design, price, turnaround time, fulfillment accuracy, member experience and ...

Dr. Reddy’s Laboratories RDY announced that it has entered into a collaboration and license agreement with Alvotech ALVO to co-develop and commercialize a biosimilar candidate to Merck’s MRK ...

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)-- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worl ...

Phase 3 trial results showed comparable efficacy between the biosimilar and the reference product. The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to ...

The Food and Drug Administration (FDA) has expanded the interchangeable designation for Yuflyma ® (adalimumab-aaty), a biosimilar to Humira ® (adalimumab), to include all presentations of the product.

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane ...